Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CID-103 in Relapsed/Refractory Multiple Myeloma
NCT04758767Phase 1Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CID-103 in multiple myeloma (MM) (3 arms), sponsored by CASI Pharmaceuticals, Inc. Primary endpoint: Adverse Events at 18 months. Started Mar 2021; status: completed.
02
Drugs
CID-103
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04758767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758767.